NHS England and NHS Improvement have revealed their intention to work much more closely together to maximise efficiencies and reduce duplication.
News
Final NICE green light for Ipsen’s Cometriq
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
Lords call for clarity on EU healthcare deal
The House of Lords EU Committee is urging the government to clarify the reciprocal healthcare arrangements for UK citizens in the EU and EU citizens in the UK post Brexit.
Six new therapies backed for EU approval
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
May backs new funding plan for NHS
Prime Minister Theresa May has voiced support for a new long-term funding plan for the National Health Service, while the DH has unveiled a capital investment of £760 million to improve buildings and services.
NHS financial state remains ‘perilous’, concludes PAC
The financial position of the NHS remains in a perilous state, largely because of the continued focus on short-term fixes, concludes a new report by the Public Accounts Committee (PAC).
Hospitals failing to test for Lynch syndrome
Hospitals across the UK are failing to test all bowel cancer patients at the time of their diagnosis for a genetic condition called Lynch syndrome, which significantly increases the risk of developing cancer over a lifetime.
Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
GSK to buy-out Novartis’ stake in consumer health JV
GlaxoSmithKline is buying Novartis’ stake in the firms’ consumer healthcare unit, the announcement coming just days after the drug giant said it would not pursue acquisition of Pfizer’s consumer healthcare business.
Industry welcomes progress on Brexit
Pharmaceutical industry representatives have applauded the decision to progress Brexit negotiations to the next phase, with the UK and EU having agreed the terms of the transition period.
Shire links with NanoMedSyn to work on new ERT
Shire has linked with US biotech NanoMedSyn to evaluate a potential enzyme replacement therapy (ERT) for an undisclosed lysosomal storage disorder.
EU clears first allogeneic stem cell therapy
TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.
GSK no longer vying for Pfizer’s consumer assets
GlaxoSmithKline has revealed that it will not bid for Pfizer’s consumer healthcare business, pulling out of the process just days after rival suitor Reckit Benckiser stepped away from a potential deal.
Tasigna cleared for use in children with rare leukemia
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
